Study on changes in urinary glucose concentrations in Type 2 diabetes patients treated with the selective SGLT2 inhibitor luseogliflozin

Trial Profile

Study on changes in urinary glucose concentrations in Type 2 diabetes patients treated with the selective SGLT2 inhibitor luseogliflozin

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Luseogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Sep 2016 Planned End Date changed from 30 Nov 2016 to 31 Oct 2017.
    • 07 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top